David Lacey
Chairman bij NURIX THERAPEUTICS, INC.
Vermogen: 1 M $ op 31-03-2024
Profiel
David L.
Lacey is currently the Chairman at Nurix Therapeutics, Inc. He is also serving as an Independent Director at Atreca, Inc., an Independent Non-Executive Director at Inbiomotion SL, an Independent Director at Arcus Biosciences, Inc., and a Venture Partner at Ysios Capital Partners SGEIC SA. Previously, Dr. Lacey held positions as an Independent Non-Executive Director at argenx SE from 2014 to 2021, a Director at Rainier Therapeutics, Inc., an Independent Director at Unity Biotechnology, Inc. from 2018 to 2020, and a Senior Vice President-Discovery Research at Amgen, Inc. from 1994 to 2011.
He also worked as an Associate at The University of Colorado and as an Assistant Professor at Jewish Hospital.
Dr. Lacey completed his undergraduate degree at The University of Colorado in 1980 and earned a doctorate from The University of Colorado School of Medicine.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ARCUS BIOSCIENCES, INC.
0.05% | 15-06-2023 | 49 252 ( 0.05% ) | 929 878 $ | 31-03-2024 |
NURIX THERAPEUTICS, INC.
0.07% | 21-03-2024 | 33 333 ( 0.07% ) | 489 995 $ | 31-03-2024 |
ATRECA, INC. CLASS A
-.--% | 13-06-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van David Lacey
| Bedrijven | Functie | Begin |
|---|---|---|
| NURIX THERAPEUTICS, INC. | Chairman | 01-08-2019 |
| ATRECA, INC. | Director/Board Member | 31-05-2016 |
| ARCUS BIOSCIENCES, INC. | Director/Board Member | 21-05-2020 |
Inbiomotion SL
 Inbiomotion SL Medical SpecialtiesHealth Technology Inbiomotion SL designs and develops diagnostic assays. It focus on genetic biomarkers, which predict the bone-specific metastases in cancer patients. The firm develops biomarker in breast cancer primary tumors for predicting the bone relapse. The company was founded by in 2010 and is headquartered in Barcelona, Spain. | Director/Board Member | 01-12-2012 |
Ysios Capital Partners SGEIC SA
 Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Private Equity Investor | 01-06-2020 |
Eerdere bekende functies van David Lacey
| Bedrijven | Functie | Einde |
|---|---|---|
| ARGENX SE | Director/Board Member | 11-05-2021 |
| UNITY BIOTECHNOLOGY, INC. | Director/Board Member | 14-12-2020 |
| AMGEN INC. | Corporate Officer/Principal | 01-01-2011 |
| The University of Colorado | Corporate Officer/Principal | - |
| ░░░░░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Opleiding van David Lacey
| The University of Colorado | Undergraduate Degree |
| The University of Colorado School of Medicine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 6 |
|---|---|
| AMGEN INC. | Health Technology |
| ATRECA, INC. | Health Technology |
| NURIX THERAPEUTICS, INC. | Health Technology |
| ARGENX SE | Health Technology |
| UNITY BIOTECHNOLOGY, INC. | Health Technology |
| ARCUS BIOSCIENCES, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Ysios Capital Partners SGEIC SA
Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Finance |
Jewish Hospital
 Jewish Hospital Hospital/Nursing ManagementHealth Services Part of Community Health Systems, Inc., Jewish Hospital is a hospital. The private company is based in Cincinnati, OH. Jewish Hospital was acquired by Mercy Health Partners, Inc. (Pennsylvania), a NPO of Community Health Systems, Inc. from Jewish Foundation of Cincinnati on March 01, 2010 for $180 million. | Health Services |
Inbiomotion SL
Inbiomotion SL Medical SpecialtiesHealth Technology Inbiomotion SL designs and develops diagnostic assays. It focus on genetic biomarkers, which predict the bone-specific metastases in cancer patients. The firm develops biomarker in breast cancer primary tumors for predicting the bone relapse. The company was founded by in 2010 and is headquartered in Barcelona, Spain. | Health Technology |
Rainier Therapeutics, Inc.
 Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Health Technology |
